ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,345
-0,05%
Bitcoin
61 474,21
0,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) Actualités

MNKD

MannKind (MNKD)

MannKind Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MNKD
DateHeureSourceTitreSymboleSociété
08/05/202422h18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
08/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
08/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
06/05/202412h05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202422h00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412h05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412h05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202412h00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
26/03/202421h05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
11/03/202411h05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
05/03/202412h05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
04/03/202419h01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
27/02/202422h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
20/02/202412h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
15/02/202412h05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/01/202412h05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
28/12/202312h00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
15/12/202322h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
07/11/202322h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Third Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
06/11/202312h15GlobeNewswire Inc.MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesNASDAQ:MNKDMannKind Corporation
31/10/202321h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023NASDAQ:MNKDMannKind Corporation
30/10/202311h15GlobeNewswire Inc.MannKind Expands Patent Portfolio With New Clofazimine Formulation PatentNASDAQ:MNKDMannKind Corporation
04/10/202303h00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MNKDMannKind Corporation
23/08/202322h52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MNKDMannKind Corporation
07/08/202322h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Second Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
01/08/202312h00GlobeNewswire Inc.MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
31/07/202322h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023NASDAQ:MNKDMannKind Corporation
22/06/202312h05GlobeNewswire Inc.MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)NASDAQ:MNKDMannKind Corporation
11/06/202314h05GlobeNewswire Inc.Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing MilestoneNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
BN
Danone
NASDAQ
MSFT
Microsoft
EU
ORA
Orange
EU
EN
Bouygues
EU
BEL20
Bel 20
EU
LR
Legrand
NYSE
JPM
JP Morgan Chase
EU
CAP
Capgemini
NYSE
KO
Coca Cola
EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
PX4
SBF 120
EU
DG
Vinci
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés